(Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug ...

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete responseToronto, Ontario--(Newsfile Corp. - ...

An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder ...

Deion Sanders was "unashamed" to open up about the effects of his bladder removal surgery in a new interview with Good Morning America. In June, the NFL legend and current Colorado Buffaloes coach ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...